REVIEW LEDGER
论文复核台
集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。
| 论文 | 元数据入排 | 图像/No. at risk 复核 | 依据 |
|---|---|---|---|
| Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan.PMID 37934081 · 2023-Dec | needs_reviewThe record describes a randomized Phase III trial in oncology (small cell lung cancer) and meets the trial design criteria, but the provided metadata (title only, no abstract) does not contain explicit signals for the required efficacy outcomes (e.g., survival, progression, recurrence). Therefore, eligibility cannot be definitively established. | pending- | The record describes a randomized Phase III trial in oncology (small cell lung cancer) and meets the trial design criteria, but the provided metadata (title only, no abstract) does not contain explicit signals for the required efficacy outcomes (e.g., survival, progression, recurrence). Therefore, eligibility cannot be definitively established. |
| Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial.PMID 37752892 · 2023-Nov | needs_reviewThe study is a secondary analysis of a Phase III randomized controlled trial comparing zanubrutinib to ibrutinib in R/R CLL/SLL, with drug intervention and human oncology context. However, it is excluded because the primary endpoint is health-related quality of life (a patient-reported outcome), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The report is classified as secondary, not primary. | pending- | The study is a secondary analysis of a Phase III randomized controlled trial comparing zanubrutinib to ibrutinib in R/R CLL/SLL, with drug intervention and human oncology context. However, it is excluded because the primary endpoint is health-related quality of life (a patient-reported outcome), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The report is classified as secondary, not primary. |
| FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety.PMID 37891616 · 2023-Oct-27 | needs_reviewThis is a protocol for a Phase III randomized trial comparing two drugs for febrile neutropenia prevention in hematologic patients. While it meets criteria for oncology, human subjects, randomization, Phase III status, and drug intervention, it does not report results for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The abstract explicitly states it is a protocol (Clinical Trial Registration, Protocol Version) and does not present efficacy data. Therefore, it is excluded as it is not an original result report. | pending- | This is a protocol for a Phase III randomized trial comparing two drugs for febrile neutropenia prevention in hematologic patients. While it meets criteria for oncology, human subjects, randomization, Phase III status, and drug intervention, it does not report results for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). The abstract explicitly states it is a protocol (Clinical Trial Registration, Protocol Version) and does not present efficacy data. Therefore, it is excluded as it is not an original result report. |
| Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.PMID 37665777 · 2023-Oct-03 | needs_reviewThe report is from a Phase III randomized trial in oncology with a drug intervention, but the abstract focuses exclusively on cardiac safety (LVEF) data and does not report any time-to-event efficacy endpoint (e.g., OS, PFS). | pending- | The report is from a Phase III randomized trial in oncology with a drug intervention, but the abstract focuses exclusively on cardiac safety (LVEF) data and does not report any time-to-event efficacy endpoint (e.g., OS, PFS). |
| A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).PMID 37777738 · 2023-Sep-30 | needs_reviewThis is a Phase II randomized trial protocol for radiation therapy (no drug intervention) with toxicity as the primary endpoint, lacking a time-to-event efficacy analysis or original results. | pending- | This is a Phase II randomized trial protocol for radiation therapy (no drug intervention) with toxicity as the primary endpoint, lacking a time-to-event efficacy analysis or original results. |
| Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial).PMID 36197757 · 2023-Aug-25 | needs_reviewThe study is a randomized Phase II/III trial with a drug intervention, but it is for rheumatoid arthritis (non-oncology) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). | pending- | The study is a randomized Phase II/III trial with a drug intervention, but it is for rheumatoid arthritis (non-oncology) and does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). |
| Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer.PMID 37282626 · 2023-Jul-31 | needs_reviewThe record is a review article summarizing multiple trials, not an original result report of a single randomized trial. It lacks primary time-to-event efficacy data (e.g., KM curves, HR) for any specific trial, which is required for eligibility. | pending- | The record is a review article summarizing multiple trials, not an original result report of a single randomized trial. It lacks primary time-to-event efficacy data (e.g., KM curves, HR) for any specific trial, which is required for eligibility. |
| Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study.PMID 36870797 · 2023-Jul | needs_reviewThe record is an eligible-type report (Phase 3b, randomized, oncology, human, drug intervention, original result). However, the abstract is missing, and the title does not explicitly state a time-to-event efficacy endpoint (e.g., OS, PFS) or mention Kaplan-Meier/HR. Metadata cannot confirm the 'time_to_event' criterion without this information. Therefore, is_eligible is set to null. | pending- | The record is an eligible-type report (Phase 3b, randomized, oncology, human, drug intervention, original result). However, the abstract is missing, and the title does not explicitly state a time-to-event efficacy endpoint (e.g., OS, PFS) or mention Kaplan-Meier/HR. Metadata cannot confirm the 'time_to_event' criterion without this information. Therefore, is_eligible is set to null. |
| Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis.PMID 37379135 · 2023-Jun-29 | needs_reviewThe study is a Phase 3 randomized trial of a drug (mirikizumab) for ulcerative colitis, which is not a malignant neoplasm (oncology). Although it meets criteria for being a human, randomized, Phase 3, original result report with a drug intervention, it fails the core oncology requirement. Additionally, no time-to-event efficacy endpoint was identified; the primary endpoints were categorical remission rates. | pending- | The study is a Phase 3 randomized trial of a drug (mirikizumab) for ulcerative colitis, which is not a malignant neoplasm (oncology). Although it meets criteria for being a human, randomized, Phase 3, original result report with a drug intervention, it fails the core oncology requirement. Additionally, no time-to-event efficacy endpoint was identified; the primary endpoints were categorical remission rates. |
| Preoperative chemoradiation-induced hematological toxicity and related vertebral dosimetry evaluations in patients with locally advanced gastric cancer: data from a phase III clinical trial.PMID 37365597 · 2023-Jun-09 | needs_reviewThe record is from a Phase III randomized trial in human oncology (gastric cancer), but it reports only hematological toxicity and dosimetry parameters. It does not report survival, progression, recurrence, death, hazard, time-to-event, or other efficacy outcomes required for eligibility. Therefore, eligibility cannot be established from the provided metadata. | pending- | The record is from a Phase III randomized trial in human oncology (gastric cancer), but it reports only hematological toxicity and dosimetry parameters. It does not report survival, progression, recurrence, death, hazard, time-to-event, or other efficacy outcomes required for eligibility. Therefore, eligibility cannot be established from the provided metadata. |
| Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.PMID 37010251 · 2023-May-20 | needs_reviewThe trial is a randomized Phase III oncology study with a drug intervention, but its primary efficacy endpoint is the percentage of patients achieving a pharmacodynamic endpoint (testosterone suppression ≤50 ng/dL) and its cumulative probability over a fixed time period (day 29 to 85). This is not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier curve or hazard ratio for such an endpoint is described. | pending- | The trial is a randomized Phase III oncology study with a drug intervention, but its primary efficacy endpoint is the percentage of patients achieving a pharmacodynamic endpoint (testosterone suppression ≤50 ng/dL) and its cumulative probability over a fixed time period (day 29 to 85). This is not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier curve or hazard ratio for such an endpoint is described. |
| ESTIMation of the ABiLity of prophylactic central compartment neck dissection to modify outcomes in low-risk differentiated thyroid cancer: a prospective randomized trial.PMID 37118818 · 2023-Apr-28 | needs_reviewThis is a protocol for a randomized Phase III trial in thyroid cancer, but it does not report results. The primary endpoint is 'excellent response' at 1 year, which is not a time-to-event outcome like OS, PFS, or DFS. While radioactive iodine is used, it is standard adjuvant therapy in both arms, and the study's intervention is surgical (prophylactic neck dissection vs. thyroidectomy alone). Therefore, it does not meet criteria for a drug intervention or time-to-event efficacy endpoint in a result report. | pending- | This is a protocol for a randomized Phase III trial in thyroid cancer, but it does not report results. The primary endpoint is 'excellent response' at 1 year, which is not a time-to-event outcome like OS, PFS, or DFS. While radioactive iodine is used, it is standard adjuvant therapy in both arms, and the study's intervention is surgical (prophylactic neck dissection vs. thyroidectomy alone). Therefore, it does not meet criteria for a drug intervention or time-to-event efficacy endpoint in a result report. |
| The success of anti-PD-1 with chemotherapy for esophageal squamous cell carcinoma.PMID 37075702 · 2023-Apr-18 | needs_reviewThe record describes a Phase III RCT with drug intervention in oncology, but the abstract does not explicitly specify a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) or Kaplan-Meier/HR data. Without this information, the time_to_event criterion cannot be established. | pending- | The record describes a Phase III RCT with drug intervention in oncology, but the abstract does not explicitly specify a time-to-event efficacy endpoint (like OS, PFS, DFS, etc.) or Kaplan-Meier/HR data. Without this information, the time_to_event criterion cannot be established. |
| Long-Term Results of a Phase 3 Randomized Prospective Trial of Erectile Tissue-Sparing Intensity-Modulated Radiation Therapy for Men With Clinically Localized Prostate Cancer.PMID 36566906 · 2023-Apr-01 | needs_reviewThe study is a Phase 3 randomized trial in oncology (prostate cancer) with a drug-related intervention (PDE5 inhibitors), but the primary efficacy endpoint is erectile function preservation, not a time-to-event endpoint like OS, PFS, or DFS. The reported secondary endpoint 'freedom from biochemical failure' is a time-to-event outcome, but it is not designated as the primary or key secondary endpoint in the abstract, and the trial's main focus is on functional preservation. | pending- | The study is a Phase 3 randomized trial in oncology (prostate cancer) with a drug-related intervention (PDE5 inhibitors), but the primary efficacy endpoint is erectile function preservation, not a time-to-event endpoint like OS, PFS, or DFS. The reported secondary endpoint 'freedom from biochemical failure' is a time-to-event outcome, but it is not designated as the primary or key secondary endpoint in the abstract, and the trial's main focus is on functional preservation. |
| Maintenance therapy in multiple myeloma: Two is not always better than one.PMID 36541138 · 2023-Apr | needs_reviewThe record is a commentary on the original phase III trial (Jenner et al.). It does not contain the primary formal results with explicit time-to-event endpoint data (e.g., OS, PFS, Kaplan-Meier, HR). Therefore, it is not eligible as an original result report for KM digitization. The 'is_eligible' criterion is set to null because the metadata cannot establish the presence of the required time-to-event endpoint in this specific document. | pending- | The record is a commentary on the original phase III trial (Jenner et al.). It does not contain the primary formal results with explicit time-to-event endpoint data (e.g., OS, PFS, Kaplan-Meier, HR). Therefore, it is not eligible as an original result report for KM digitization. The 'is_eligible' criterion is set to null because the metadata cannot establish the presence of the required time-to-event endpoint in this specific document. |
| Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG).PMID 37084329 · 2023-Apr | needs_reviewWhile the record describes a Phase III randomized oncology trial (S1400I), the abstract focuses exclusively on adverse event visualization methodology. It does not report any survival, progression, recurrence, death, hazard, time-to-event, or other efficacy outcomes, which are required for inclusion in the Kaplan-Meier digitization cohort. | pending- | While the record describes a Phase III randomized oncology trial (S1400I), the abstract focuses exclusively on adverse event visualization methodology. It does not report any survival, progression, recurrence, death, hazard, time-to-event, or other efficacy outcomes, which are required for inclusion in the Kaplan-Meier digitization cohort. |
| Roussel M, Lauwers-Cances V, Macro M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757.PMID 36893003 · 2023-Mar-09 | needs_reviewMetadata indicates an oncology randomized phase 3 trial, but lacks abstract or keywords to confirm human subjects and specific survival/progression outcomes. Insufficient to establish eligibility without further review. | pending- | Metadata indicates an oncology randomized phase 3 trial, but lacks abstract or keywords to confirm human subjects and specific survival/progression outcomes. Insufficient to establish eligibility without further review. |
| Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.PMID 36759721 · 2023-Mar | needs_reviewThe record describes a biomarker subgroup analysis of the phase III TRIBE2 randomized trial, reporting OS and PFS outcomes. While it meets the oncology, human, randomized, and phase criteria, and includes relevant survival outcomes, the report is a secondary/subgroup analysis, not the primary or definitive efficacy report of the trial. Eligibility for Kaplan-Meier digitization requires tracing back to the primary trial report, which is not provided here. | pending- | The record describes a biomarker subgroup analysis of the phase III TRIBE2 randomized trial, reporting OS and PFS outcomes. While it meets the oncology, human, randomized, and phase criteria, and includes relevant survival outcomes, the report is a secondary/subgroup analysis, not the primary or definitive efficacy report of the trial. Eligibility for Kaplan-Meier digitization requires tracing back to the primary trial report, which is not provided here. |
| STAR-TREC: An International Three-arm Multicentre, Partially Randomised Controlled Trial Incorporating an External Pilot.PMID 36577551 · 2023-Feb | needs_reviewRecord is a protocol abstract for a Phase III randomised trial in oncology with time-to-event secondary endpoints, but it does not present formal trial results. Additionally, the drug intervention criterion cannot be clearly established as the trial compares organ preservation strategies (which may include chemoradiation) versus surgery, and the primary endpoint is not time-to-event. Therefore, it is excluded as a protocol without results. | pending- | Record is a protocol abstract for a Phase III randomised trial in oncology with time-to-event secondary endpoints, but it does not present formal trial results. Additionally, the drug intervention criterion cannot be clearly established as the trial compares organ preservation strategies (which may include chemoradiation) versus surgery, and the primary endpoint is not time-to-event. Therefore, it is excluded as a protocol without results. |
| Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study).PMID 36220461 · 2023-Jan | needs_reviewThe trial is a randomized Phase III oncology study in humans, but the abstract reports only short-term morbidity and pathological outcomes. It explicitly states that cancer outcome results (which would include time-to-event endpoints) are pending. The intervention includes chemoradiotherapy, but the trial's primary comparison is between two surgical strategies (local excision vs. total mesorectal excision), and the abstract does not present the time-to-event efficacy data required for inclusion. | pending- | The trial is a randomized Phase III oncology study in humans, but the abstract reports only short-term morbidity and pathological outcomes. It explicitly states that cancer outcome results (which would include time-to-event endpoints) are pending. The intervention includes chemoradiotherapy, but the trial's primary comparison is between two surgical strategies (local excision vs. total mesorectal excision), and the abstract does not present the time-to-event efficacy data required for inclusion. |
| Safety of levofloxacin as an antibiotic prophylaxis in the induction phase of children newly diagnosed with acute lymphoblastic leukemia: an interim analysis of a randomized, open-label trial in Brazil.PMID 36750202 · 2023 | needs_reviewThe study is a randomized phase 3 trial in pediatric ALL with a drug intervention (levofloxacin) and reports original results. However, the primary and secondary endpoints are safety and adverse events (CPE colonization, C. difficile diarrhea, febrile neutropenia), not time-to-event efficacy outcomes (e.g., OS, PFS, DFS). There is no mention of Kaplan-Meier analysis or hazard ratios for time-to-event endpoints. Therefore, it does not meet the inclusion criteria for a primary/key secondary time-to-event efficacy endpoint. | pending- | The study is a randomized phase 3 trial in pediatric ALL with a drug intervention (levofloxacin) and reports original results. However, the primary and secondary endpoints are safety and adverse events (CPE colonization, C. difficile diarrhea, febrile neutropenia), not time-to-event efficacy outcomes (e.g., OS, PFS, DFS). There is no mention of Kaplan-Meier analysis or hazard ratios for time-to-event endpoints. Therefore, it does not meet the inclusion criteria for a primary/key secondary time-to-event efficacy endpoint. |
| Safety and efficacy of dendritic cell vaccine for COVID-19 prevention after 1-Year follow-up: phase I and II clinical trial final result.PMID 37404828 · 2023 | needs_reviewThe record reports on a COVID-19 vaccine trial, not an oncology trial. It lacks a primary/key secondary time-to-event efficacy endpoint (like OS, PFS) and is not a drug intervention. Phase is combined Phase I/II, not Phase III/IIIb or definitive Phase II/III. | pending- | The record reports on a COVID-19 vaccine trial, not an oncology trial. It lacks a primary/key secondary time-to-event efficacy endpoint (like OS, PFS) and is not a drug intervention. Phase is combined Phase I/II, not Phase III/IIIb or definitive Phase II/III. |
| Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.PMID 36753353 · 2022-Dec | needs_reviewThe record describes a subgroup analysis of a Phase III randomized trial (ARAMIS) with drug intervention and time-to-event endpoints, but it is not the original primary result report of the trial. It is a secondary analysis focusing on a specific patient population, thus excluded per criteria. | pending- | The record describes a subgroup analysis of a Phase III randomized trial (ARAMIS) with drug intervention and time-to-event endpoints, but it is not the original primary result report of the trial. It is a secondary analysis focusing on a specific patient population, thus excluded per criteria. |
| Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment.PMID 36114096 · 2022-Nov | needs_reviewWhile the study meets criteria for oncology, human, randomized, Phase 3, drug intervention, and original result, the abstract does not explicitly present a primary time-to-event efficacy endpoint (like OS or PFS with KM or HR) for the main trial population. The reported efficacy comparison is described generally ('difference in treatment efficacy... was similar to that among the overall study population'), but the specific endpoint and its time-to-event nature are not confirmed. Therefore, eligibility cannot be fully established. | pending- | While the study meets criteria for oncology, human, randomized, Phase 3, drug intervention, and original result, the abstract does not explicitly present a primary time-to-event efficacy endpoint (like OS or PFS with KM or HR) for the main trial population. The reported efficacy comparison is described generally ('difference in treatment efficacy... was similar to that among the overall study population'), but the specific endpoint and its time-to-event nature are not confirmed. Therefore, eligibility cannot be fully established. |
| The obesity paradox: Retinopathy, obesity, and circulating risk markers in youth with type 2 diabetes in the TODAY Study.PMID 36150365 · 2022-Nov | needs_reviewThe record describes a non-oncology clinical trial (TODAY Study) focused on type 2 diabetes and diabetic retinopathy in adolescents. Although it is a randomized, Phase III study in humans, the subject matter and outcomes are not relevant to oncology Kaplan-Meier digitization. | pending- | The record describes a non-oncology clinical trial (TODAY Study) focused on type 2 diabetes and diabetic retinopathy in adolescents. Although it is a randomized, Phase III study in humans, the subject matter and outcomes are not relevant to oncology Kaplan-Meier digitization. |
| Re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial.PMID 35902289 · 2022-Oct | needs_reviewThe record is a Phase III randomized trial with a time-to-event endpoint (DFS) in human prostate cancer. However, the abstract is empty and the provided metadata (including the deterministic review's 'drug_intervention: false' signal) does not contain explicit evidence that a systemic drug intervention was part of the trial's control or experimental arms. The trial involves 'Androgen Deprivation' which could be a drug intervention (e.g., androgen antagonists), but this is not explicitly confirmed as a drug-containing intervention in the provided data. Therefore, eligibility cannot be confirmed. | pending- | The record is a Phase III randomized trial with a time-to-event endpoint (DFS) in human prostate cancer. However, the abstract is empty and the provided metadata (including the deterministic review's 'drug_intervention: false' signal) does not contain explicit evidence that a systemic drug intervention was part of the trial's control or experimental arms. The trial involves 'Androgen Deprivation' which could be a drug intervention (e.g., androgen antagonists), but this is not explicitly confirmed as a drug-containing intervention in the provided data. Therefore, eligibility cannot be confirmed. |
| Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.PMID 35963941 · 2022-Oct | needs_reviewThe record is a secondary biomarker analysis from a Phase III randomized trial. While it meets criteria for oncology, human, randomized, phase3, drug intervention, and is an original result, it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) and associated statistics (Kaplan-Meier, HR) for the primary/key secondary endpoint. The deterministic review correctly identified the absence of a time-to-event signal. | pending- | The record is a secondary biomarker analysis from a Phase III randomized trial. While it meets criteria for oncology, human, randomized, phase3, drug intervention, and is an original result, it lacks the required time-to-event efficacy endpoint (e.g., OS, PFS) and associated statistics (Kaplan-Meier, HR) for the primary/key secondary endpoint. The deterministic review correctly identified the absence of a time-to-event signal. |
| Effect of interval between neoadjuvant chemoradiotherapy and surgery on disease recurrence and survival in rectal cancer: long-term results of a randomized clinical trial.PMID 36254732 · 2022-Sep-02 | needs_reviewEligibility requires explicit drug intervention. This trial compares timing intervals after chemoradiotherapy (CRT), not a drug regimen. The abstract does not specify drug components of CRT (e.g., fluoropyrimidine), making drug intervention unconfirmed. Metadata cannot establish this criterion without inference. | pending- | Eligibility requires explicit drug intervention. This trial compares timing intervals after chemoradiotherapy (CRT), not a drug regimen. The abstract does not specify drug components of CRT (e.g., fluoropyrimidine), making drug intervention unconfirmed. Metadata cannot establish this criterion without inference. |
| Re: Chemoradiotherapy in Muscle-invasive Bladder Cancer (BC2001): 10-year Follow-up of a Phase 3 Randomised Controlled Trial.PMID 35787935 · 2022-Sep | needs_reviewThe record is from a Phase III randomized controlled trial in human oncology, but the provided abstract is empty and no keywords or MeSH terms explicitly signal the presence of survival, progression, recurrence, death, hazard, or other time-to-event efficacy outcomes. Without abstract content or other data confirming such outcomes, eligibility cannot be determined. | pending- | The record is from a Phase III randomized controlled trial in human oncology, but the provided abstract is empty and no keywords or MeSH terms explicitly signal the presence of survival, progression, recurrence, death, hazard, or other time-to-event efficacy outcomes. Without abstract content or other data confirming such outcomes, eligibility cannot be determined. |
| Benefit of a flash dose of corticosteroids in digestive surgical oncology: a multicenter, randomized, double blind, placebo-controlled trial (CORTIFRENCH).PMID 35999521 · 2022-Aug-23 | needs_reviewThe study is a Phase III randomized oncology trial with planned OS and DFS endpoints, but it is a protocol without results. Furthermore, the intervention (perioperative corticosteroid flash dose) is a supportive care measure, not a standard systemic drug therapy for the cancer, and the primary endpoint is a safety/morbidity outcome. | pending- | The study is a Phase III randomized oncology trial with planned OS and DFS endpoints, but it is a protocol without results. Furthermore, the intervention (perioperative corticosteroid flash dose) is a supportive care measure, not a standard systemic drug therapy for the cancer, and the primary endpoint is a safety/morbidity outcome. |
| Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres.PMID 35513132 · 2022-Jul | needs_reviewWhile the record is from a Phase III randomized oncology trial, the abstract does not report any survival, progression, recurrence, death, or other time-to-event efficacy outcomes required for eligibility. It is a technical planning quality assurance study. | pending- | While the record is from a Phase III randomized oncology trial, the abstract does not report any survival, progression, recurrence, death, or other time-to-event efficacy outcomes required for eligibility. It is a technical planning quality assurance study. |
| Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.PMID 35143644 · 2022-Jun-14 | needs_reviewThe trial is a Phase III randomized controlled trial in oncology (hematological malignancy) with time-to-event endpoints (GRFS, OS, PFS) and reports original results. However, the core intervention is a post-transplant immunosuppressive regimen (cyclophosphamide, cyclosporine, mycophenolic acid) for GVHD prevention, not a primary antineoplastic drug therapy for the malignancy itself. The review criteria require a 'drug-containing intervention' for the malignancy. This study is ambiguous on whether the immunosuppressive drugs are considered the 'drug intervention' in the oncologic sense required for eligibility. Therefore, cannot definitively set is_eligible to true without clarifying this specific criterion. | pending- | The trial is a Phase III randomized controlled trial in oncology (hematological malignancy) with time-to-event endpoints (GRFS, OS, PFS) and reports original results. However, the core intervention is a post-transplant immunosuppressive regimen (cyclophosphamide, cyclosporine, mycophenolic acid) for GVHD prevention, not a primary antineoplastic drug therapy for the malignancy itself. The review criteria require a 'drug-containing intervention' for the malignancy. This study is ambiguous on whether the immunosuppressive drugs are considered the 'drug intervention' in the oncologic sense required for eligibility. Therefore, cannot definitively set is_eligible to true without clarifying this specific criterion. |
| [The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab].PMID 35758127 · 2022-Jun | needs_reviewThe abstract describes a randomized, phase III, drug-intervention trial in oncology. However, it does not explicitly report any time-to-event efficacy endpoint (OS, PFS, DFS, HR, or Kaplan-Meier results). The deterministic review also flagged a lack of time-to-event signal. Eligibility cannot be confirmed without explicit efficacy outcome data. | pending- | The abstract describes a randomized, phase III, drug-intervention trial in oncology. However, it does not explicitly report any time-to-event efficacy endpoint (OS, PFS, DFS, HR, or Kaplan-Meier results). The deterministic review also flagged a lack of time-to-event signal. Eligibility cannot be confirmed without explicit efficacy outcome data. |
| CDK12 promotes tumorigenesis but induces vulnerability to therapies inhibiting folate one-carbon metabolism in breast cancer.PMID 35550508 · 2022-May-12 | needs_reviewThe record describes a retrospective biomarker subgroup analysis from a Phase III randomized trial. It does not report a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR for the overall trial population. The outcome analyzed is distant metastasis rate. | pending- | The record describes a retrospective biomarker subgroup analysis from a Phase III randomized trial. It does not report a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR for the overall trial population. The outcome analyzed is distant metastasis rate. |
| Re: Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients with Localized Prostate Cancer: Results from the FLAME Randomized Phase III Trial.PMID 35105476 · 2022-May | needs_reviewThe record is identified as a randomized, Phase III oncology trial (FLAME trial) in humans, but the provided abstract is empty and no outcome data (survival, progression, etc.) are described in the metadata to confirm eligibility for KM digitization. The title indicates it is a 'Results' article, but the absence of an abstract or outcome signal prevents definitive inclusion. | pending- | The record is identified as a randomized, Phase III oncology trial (FLAME trial) in humans, but the provided abstract is empty and no outcome data (survival, progression, etc.) are described in the metadata to confirm eligibility for KM digitization. The title indicates it is a 'Results' article, but the absence of an abstract or outcome signal prevents definitive inclusion. |
| Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.PMID 34507355 · 2022-Apr-12 | needs_reviewThe record is from a randomized Phase III trial in oncology (MPNs) with a drug intervention, but the abstract reports no time-to-event efficacy endpoint (OS, PFS, DFS, etc.), Kaplan-Meier analysis, or hazard ratio. The primary aim and results are about molecular and clinicohematologic responses, not the required efficacy endpoint for inclusion. | pending- | The record is from a randomized Phase III trial in oncology (MPNs) with a drug intervention, but the abstract reports no time-to-event efficacy endpoint (OS, PFS, DFS, etc.), Kaplan-Meier analysis, or hazard ratio. The primary aim and results are about molecular and clinicohematologic responses, not the required efficacy endpoint for inclusion. |
| SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool.PMID 34686472 · 2022-Mar | needs_reviewThe record describes an ongoing randomized Phase II/III trial of a drug-containing regimen in oncology, but the abstract does not report any time-to-event efficacy results (e.g., OS, PFS, KM curves, HR). It is a protocol/study description without primary or secondary efficacy outcome data. | pending- | The record describes an ongoing randomized Phase II/III trial of a drug-containing regimen in oncology, but the abstract does not report any time-to-event efficacy results (e.g., OS, PFS, KM curves, HR). It is a protocol/study description without primary or secondary efficacy outcome data. |
| Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.PMID 35105329 · 2022-Feb-01 | needs_reviewThe study is a randomized Phase III oncology trial with a drug intervention (biosimilar bevacizumab) and reports original results, but the primary efficacy endpoint is overall response rate (ORR), not a time-to-event endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). The deterministic review correctly identified the absence of time-to-event signal. | pending- | The study is a randomized Phase III oncology trial with a drug intervention (biosimilar bevacizumab) and reports original results, but the primary efficacy endpoint is overall response rate (ORR), not a time-to-event endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). The deterministic review correctly identified the absence of time-to-event signal. |
| Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.PMID 34971577 · 2022-Jan | needs_reviewThe study is a Phase III randomized trial of a drug for acute graft-versus-host disease (GVHD) following HSCT for hematological malignancy. However, the primary efficacy endpoint is Overall Response Rate (ORR) at day 28, which is a binary outcome, not a time-to-event endpoint like OS, PFS, DFS, etc. No time-to-event endpoints are reported or mentioned in the abstract. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint. | pending- | The study is a Phase III randomized trial of a drug for acute graft-versus-host disease (GVHD) following HSCT for hematological malignancy. However, the primary efficacy endpoint is Overall Response Rate (ORR) at day 28, which is a binary outcome, not a time-to-event endpoint like OS, PFS, DFS, etc. No time-to-event endpoints are reported or mentioned in the abstract. Therefore, it does not meet the core requirement for a time-to-event efficacy endpoint. |
| Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma.PMID 34454995 · 2021-Dec | needs_reviewWhile the study is from a relevant Phase III randomized trial with a drug intervention, this specific report is a subgroup analysis focusing on liver function and its correlation with differential survival benefits. It does not provide the original primary or key secondary time-to-event efficacy results required for inclusion. | pending- | While the study is from a relevant Phase III randomized trial with a drug intervention, this specific report is a subgroup analysis focusing on liver function and its correlation with differential survival benefits. It does not provide the original primary or key secondary time-to-event efficacy results required for inclusion. |
| The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.PMID 34912120 · 2021-Dec | needs_reviewPrimary efficacy endpoint is objective response rate (ORR), not a time-to-event endpoint. Study is eligible otherwise but requires a primary/key secondary time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP, or HR from KM) for inclusion. The time-to-event criterion cannot be established from the provided text. | pending- | Primary efficacy endpoint is objective response rate (ORR), not a time-to-event endpoint. Study is eligible otherwise but requires a primary/key secondary time-to-event endpoint (OS, PFS, DFS, EFS, RFS, TTP, or HR from KM) for inclusion. The time-to-event criterion cannot be established from the provided text. |
| RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.PMID 34269067 · 2021-Nov | needs_reviewThe record describes a Phase III, randomized, drug-intervention trial in esophageal cancer, meeting core oncology, human, randomization, and phase criteria. However, the title and abstract do not explicitly report results for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) nor present Kaplan-Meier curves or hazard ratios. The document is identified as a protocol/rationale ('study described here'), not a formal result report. Therefore, is_eligible is set to null due to insufficient evidence for the time_to_event and original_result criteria. | pending- | The record describes a Phase III, randomized, drug-intervention trial in esophageal cancer, meeting core oncology, human, randomization, and phase criteria. However, the title and abstract do not explicitly report results for a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) nor present Kaplan-Meier curves or hazard ratios. The document is identified as a protocol/rationale ('study described here'), not a formal result report. Therefore, is_eligible is set to null due to insufficient evidence for the time_to_event and original_result criteria. |
| Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.PMID 34048027 · 2021-Oct | needs_reviewWhile the record describes an oncology, human, randomized, Phase III drug trial, the abstract does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. It is a pharmacogenomic subgroup analysis of SNP-treatment interactions, not a primary efficacy result report. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort. | pending- | While the record describes an oncology, human, randomized, Phase III drug trial, the abstract does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. It is a pharmacogenomic subgroup analysis of SNP-treatment interactions, not a primary efficacy result report. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort. |
| AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.PMID 34254530 · 2021-Oct | needs_reviewThe record describes the protocol/design of a Phase III randomized oncology trial and an early biomarker study within it. It does not report the primary or secondary time-to-event efficacy outcomes (survival, progression, etc.) required for inclusion in a Kaplan-Meier digitization cohort. | pending- | The record describes the protocol/design of a Phase III randomized oncology trial and an early biomarker study within it. It does not report the primary or secondary time-to-event efficacy outcomes (survival, progression, etc.) required for inclusion in a Kaplan-Meier digitization cohort. |
| Has the time come for routine use of PET/CT for guiding treatment of biochemical recurrence after radical prostatectomy? RE: JaniAB, et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet. 2021 May 22;55:1895-1904.PMID 34633894 · 2021-Oct | needs_reviewThe record describes a Phase 2/3 randomized controlled trial for prostate cancer, meeting basic oncology, human, randomized, and phase criteria. However, the abstract and metadata do not explicitly mention a time-to-event endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR) or a drug intervention. The intervention is PET/CT imaging to guide salvage radiotherapy, not a drug. Without clear evidence of a drug-containing arm and a time-to-event primary/key secondary endpoint, eligibility cannot be confirmed. | pending- | The record describes a Phase 2/3 randomized controlled trial for prostate cancer, meeting basic oncology, human, randomized, and phase criteria. However, the abstract and metadata do not explicitly mention a time-to-event endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR) or a drug intervention. The intervention is PET/CT imaging to guide salvage radiotherapy, not a drug. Without clear evidence of a drug-containing arm and a time-to-event primary/key secondary endpoint, eligibility cannot be confirmed. |
| EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers.PMID 33199443 · 2021-Sep | needs_reviewThe study meets most inclusion criteria: it is a Phase III, randomized, human oncology trial with a drug-containing intervention (panitumumab + chemotherapy). However, the abstract does not provide explicit reporting of a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP, nor does it mention Kaplan-Meier analysis or hazard ratios. The deterministic review correctly flagged a lack of time-to-event signal, so eligibility cannot be confirmed without verifying the full-text for the presence of these results. | pending- | The study meets most inclusion criteria: it is a Phase III, randomized, human oncology trial with a drug-containing intervention (panitumumab + chemotherapy). However, the abstract does not provide explicit reporting of a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, or TTP, nor does it mention Kaplan-Meier analysis or hazard ratios. The deterministic review correctly flagged a lack of time-to-event signal, so eligibility cannot be confirmed without verifying the full-text for the presence of these results. |
| Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial.PMID 33320286 · 2021-Sep | needs_reviewThe record describes a secondary analysis of guideline impact and adoption within a Phase III randomized controlled trial (HYPOSIB). While it is a definitive oncology trial, the reported outcomes are related to treatment adoption and patient characteristics, not the survival, progression, recurrence, death, or other efficacy outcomes required for inclusion. | pending- | The record describes a secondary analysis of guideline impact and adoption within a Phase III randomized controlled trial (HYPOSIB). While it is a definitive oncology trial, the reported outcomes are related to treatment adoption and patient characteristics, not the survival, progression, recurrence, death, or other efficacy outcomes required for inclusion. |
| [Not Available].PMID 34318458 · 2021-Aug | needs_reviewMetadata confirms oncology, human, randomized, Phase III. However, the abstract is empty and deterministic review found no reliable time-to-event signal or drug intervention signal. Cannot establish eligibility without explicit confirmation of a drug-containing intervention and a primary/key secondary time-to-event endpoint from the original report. | pending- | Metadata confirms oncology, human, randomized, Phase III. However, the abstract is empty and deterministic review found no reliable time-to-event signal or drug intervention signal. Cannot establish eligibility without explicit confirmation of a drug-containing intervention and a primary/key secondary time-to-event endpoint from the original report. |
| Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases.PMID 34333237 · 2021-Aug | needs_reviewThe record is eligible for oncology, human, randomized, phase 3, and time-to-event, but the drug intervention is not explicitly described or evaluated in this report (it's a biomarker sub-study). Therefore, it does not meet the inclusion criteria for a primary drug-efficacy report. | pending- | The record is eligible for oncology, human, randomized, phase 3, and time-to-event, but the drug intervention is not explicitly described or evaluated in this report (it's a biomarker sub-study). Therefore, it does not meet the inclusion criteria for a primary drug-efficacy report. |
| Feasibility of a prospective real-time monitoring system capturing real-world data from elderly patients with acute myeloid leukemia.PMID 42830877 · 2026-Dec | needs_review已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。 | pending- | 已见 Phase III 随机试验与 time-to-event 终点,但药物干预证据不足,需复核。 |